Granulocyte-Macrophage Colony Stimulating Factor and Inflammatory Bowel Disease: Establishing a Connection
Author:
- Glenn DranoffGDGlenn Dranoff
- 31 July 2011
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 141 (1) , 28-31
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Defective Leukocyte GM-CSF Receptor (CD116) Expression and Function in Inflammatory Bowel DiseaseGastroenterology, 2011
- The Evolving War on CancerCell, 2011
- Phase I trial of sargramostim in pediatric Crohn's diseaseInflammatory Bowel Diseases, 2010
- Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's diseaseJournal of Experimental Medicine, 2009
- Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 studyGut, 2009
- The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor ActivationCell, 2008
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Defective acute inflammation in Crohn's disease: a clinical investigationThe Lancet, 2006
- Sargramostim for Active Crohn's DiseaseNew England Journal of Medicine, 2005
- Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factorThe Lancet, 2002